Depression is a major public health concern and one of the priorities in the field of psychiatry, notably to develop therapeutic strategies with a better efficacy than currently available antidepressant drugs.

A recent study led by Bruno GUIARD, professor at the University of Toulouse III, Paul Sabatier (Research Center On Animal Cognition / Center of Integrative Biology), provides experimental evidence that metformin, an oral anti diabetic, produces anxiolytic and antidepressant-like effects in insulin-resistant mice. This finding is particularly interesting in light of the therapeutic limitations of antidepressant drugs and pave the way to the identification of new targets for the treatment of psychiatric disorders in relation with the peripheral metabolism.

This finding is particularly interesting in light of the therapeutic limitations of antidepressant drugs and pave the way to the identification of new targets for the treatment of psychiatric disorders in relation with the peripheral metabolism. This study has been published recently in Journal of Neuroscience (J Neurosci. 2019 Jun 3. pii: 2904-18. doi:10.1523/JNEUROSCI.2904-18.2019).

Read more:

• "How a diabetes drug may reduce anxiety symptoms" MedicalNewsToday
• "Diabetes drug alleviates anxiety in mice: Findings could have implications for patients with metabolic and mental disorders." ScienceDaily